Funded by the National Institute of General Medical Sciences since 1992, the program has a long and distinguished record of excellence in training leaders in clinical pharmacology and transitional therapeutics who have assumed prominent roles in academia, the pharmaceutical industry and biotechnology, and regulatory agencies.
“Our training program has significantly evolved over the years such that it now represents one of the strongest, most comprehensive, and cutting-edge training programs in clinical pharmacology and translational therapeutics,” said Zeruesenay Desta, PhD. Desta is a professor of medicine and co-directs the program with Michael Eadon, MD.
Exceptional institutional support is in place for this training program, according to the co-directors.
“Our program has benefitted from committed, experienced and diverse investigators from IU, Purdue and industry, supported by peer-reviewed funding, as well as significant institutional support from the IU School of Medicine and the Department of Medicine,” Desta and Eadon wrote. “We strongly believe this T32 program will continue to significantly contribute to the national effort of filling a critical need of well-trained clinical scientist that can augment the translation of new therapies into clinical practice and to ensure the safe and effective use of medications."
The views expressed in this content represent the perspective and opinions of the author and may or may not represent the position of Indiana University School of Medicine.
Hannah Calkins is the communications manager for the Department of Medicine.